[go: up one dir, main page]

KR900702033A - 클론된 신장염 항원 - Google Patents

클론된 신장염 항원

Info

Publication number
KR900702033A
KR900702033A KR1019900700817A KR900700817A KR900702033A KR 900702033 A KR900702033 A KR 900702033A KR 1019900700817 A KR1019900700817 A KR 1019900700817A KR 900700817 A KR900700817 A KR 900700817A KR 900702033 A KR900702033 A KR 900702033A
Authority
KR
South Korea
Prior art keywords
sequence
recombinant dna
functional derivative
molecule
animal
Prior art date
Application number
KR1019900700817A
Other languages
English (en)
Inventor
에이. 스미스 잔
레이초우드리 레이크티마
엘. 나일즈 잔
Original Assignee
원본미기재
더 제네랄 호스피탈 코오퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 제네랄 호스피탈 코오퍼레이션 filed Critical 원본미기재
Publication of KR900702033A publication Critical patent/KR900702033A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

클론된 신장염 항원
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 역상 HPLC에 의해 분리된 gp330 트립신 분해 펩티드의 HPLC추적을 도시한다. 제2도는 gp330으로 부터 유도된 다섯개의 트립신 분해 펩티드의 아미노산 서열을 도시한다. 제3도는 gp330 DNA 단편(1.4, 0.6 및 0.4kb)의 제한 지도를 도시하며 23- 염기 올리고뉴클레오티드 프로브에 대한 홍성화 부위를 명시한다.

Claims (15)

  1. 하이만 신장염 항원인 gp330, 또는 그의 기능상의 유도체를 코드화하는 유전서열로 이루어지는 재조합 DNA 분자.
  2. 제1항에 있어서, 상기 유전서열이 제4도의 서열을 포함하는 것을 특징으로 하는 재조합 DNA 분자.
  3. 제1항에 있어서, 상기 유전서열이 제8도의 서열을 포함하는 것을 특징으로 하는 재조합 DNA 분자.
  4. 제1항에 있어서, 상기 유전서열이 제9도의 서열을 포함하는 것을 특징으로 하는 재조합 DNA 분자.
  5. 제1항에 있어서, 복제가능한 벡터인 것을 특징으로 하는 재조합 DNA 분자.
  6. 제5항의 벡터로 형질전환된 숙주.
  7. 실질적으로 정제되고 쥐로부터 유래한 불순물이 없는 하이만 신장염 항원 분자인 gp330, 또는 그의 기능상의 유도체.
  8. 제7항에 있어서, 제5도에 도시된 아미노산 서열로 이루어지는 것을 특징으로 하는 분자.
  9. 제7항에 있어서, 제8도에 도시된 아미노산 서열로 이루어지는 것을 특징으로 하는 분자.
  10. 제7항에 있어서, 제9도에 도시된 아미노산 서열로 이루어지는 것을 특징으로 하는 분자.
  11. (a)제5항의 벡터로 형질전환된 숙주를 얻는 단계, (b)상기 유전서열의 발현을 허용하기에 충분한 조건하에서 상기 숙주를 성장시키는 단계, 그리고 (c)상기 발현된 gp330 또는 그의 기능상의 유도체를 회수하는 단계로 이루어지는, gp330 또는 그의 기능상의 유도체의 제조방법.
  12. 동물의 LDL수용체 유전자의 유전적 이상의 검출방법으로서,(a)상기 이상을 보이는 것으로 추측되는 동물로부터 DNA를 분리하는 단계; (b)단계(a)에서 얻은 상기 DNA를 gp330 또는 그의 기능상의 유도체를 코드화하는 DNA 서열과, 혼성화 조건하에서 접촉시키는 단계; 그리고 (c)상기 gp330DNA서열과 상기 분리된 DNA와의 혼성화를 검출하는 단계로 이루어지는 방법.
  13. 제12항에 있어서, 상기 유전적 이상이 가족성 과콜레스테롤 혈증인 것을 특징으로 하는 방법.
  14. 외상을 치료하기에 유효한 양으로 존재하는 (a)gp330 또는 그의 기능상의 유도체, 및 (b)약학적으로 허용가능한 담체로 이루어지는 약학조성물을 동물에 투여하는 것으로 이루어지는 외상의 치료방법.
  15. 궤양을 방지 또는 치료하기에 효과적인 양으로 존재하는 (a)gp330 또는 그의 기능상의 유도체 및 (b)약학적으로 허용가능한 담채로 이루어지는 약학조성물을 동물에 투여하는 것으로 이루어지는, 동물의 위궤양을 방지 또는 치료하기 위한 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700817A 1988-08-23 1989-08-23 클론된 신장염 항원 KR900702033A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23521188A 1988-08-23 1988-08-23
US235,211 1988-08-23
US31368289A 1989-02-22 1989-02-22
US313.682 1989-02-22
US07/396,697 US5208144A (en) 1988-08-23 1989-08-22 Method for detection of human dna containing the gene encoding low density lipoprotein receptor
US396,697 1989-08-22
PCT/US1989/003621 WO1990002207A1 (en) 1988-08-23 1989-08-23 Cloned nephritis antigen

Publications (1)

Publication Number Publication Date
KR900702033A true KR900702033A (ko) 1990-12-05

Family

ID=27398695

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700817A KR900702033A (ko) 1988-08-23 1989-08-23 클론된 신장염 항원

Country Status (7)

Country Link
US (1) US5208144A (ko)
JP (1) JPH04500603A (ko)
KR (1) KR900702033A (ko)
AU (1) AU623930B2 (ko)
DK (1) DK27591D0 (ko)
FI (1) FI910852A0 (ko)
WO (1) WO1990002207A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723556B1 (en) * 1982-12-02 2004-04-20 Cornell Research Foundation, Inc. Nucleic acid encoding a fragment of bovine luteinizing hormone/chorionic gonadotropin receptor
US5304636A (en) * 1987-04-14 1994-04-19 Boehringer Ingelheim International Gmbh Receptor for the human rhinovirus minor group
US5603932A (en) * 1987-04-14 1997-02-18 Boehringer Ingelheim International Gmbh Receptor of the minor human rhinovirus receptor group
US5496926A (en) 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
EP0792159A4 (en) * 1994-11-23 2003-01-02 Rhone Poulenc Rorer Pharma Human calcium sensor protein, fragments thereof and dna encoding same
DK0795605T3 (da) * 1994-11-30 2006-10-09 Nippon Chemiphar Co Denatureret lavdensitetslipoprotein-receptor
US5523208A (en) * 1994-11-30 1996-06-04 The Board Of Trustees Of The University Of Kentucky Method to discover genetic coding regions for complementary interacting proteins by scanning DNA sequence data banks
WO2006036946A2 (en) * 2004-09-27 2006-04-06 Fonar Corporation Magnetic resonance imaging system, apparatus and associated methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7907292A (nl) * 1979-10-01 1981-04-03 Bogey Bv Houder met transportinrichting voor bandvormige informatiedrager en inrichting voor het schrijven, lezen of wissen van informatie, te gebruiken met zulk een houder.
WO1985000369A1 (en) * 1983-07-05 1985-01-31 Chiron Corporation Hybrid dna synthesis of epidermal growth factor
CA1263619A (en) * 1984-10-09 1989-12-05 Ryuji Marumoto Dna, production and use thereof
US4745060A (en) * 1984-12-28 1988-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the detection of Familial Hypercholesterolemia
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof

Also Published As

Publication number Publication date
AU623930B2 (en) 1992-05-28
AU4212789A (en) 1990-03-23
FI910852A0 (fi) 1991-02-22
DK27591A (da) 1991-02-18
DK27591D0 (da) 1991-02-18
WO1990002207A1 (en) 1990-03-08
JPH04500603A (ja) 1992-02-06
US5208144A (en) 1993-05-04

Similar Documents

Publication Publication Date Title
Lozier et al. Complete amino acid sequence of human plasma beta 2-glycoprotein I.
Swinnen et al. Facile, Fmoc-compatible solid-phase synthesis of peptide C-terminal thioesters
Bringman et al. Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes
Tomassini et al. Isolation of a receptor protein involved in attachment of human rhinoviruses
Karkhanis et al. Allergic encephalomyelitis. Isolation of an encephalitogenic peptide active in the monkey.
Friedman et al. Cholera toxin inhibits interferon action
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
DK203489A (da) Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme
KR960705041A (ko) Tgf 수용체 족 및/ 또는 bmp 수용체 족에 속하는 액티빈 수용체 유사 키나제(alk) (activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family)
Bradbury et al. Comparison of the analgesic properties of lipotropin C-fragment and stabilized enkephalins in the rat
BR9609006A (pt) Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
NO2009022I1 (no) Protein-D ; Se annet dokument (det siste)
Sieber Modification of tryptophan residues during acidolysis of 4-methoxy-2, 3, 6-trimethylbenzenesulfonyl groups. Effects of scavengers
KR900702033A (ko) 클론된 신장염 항원
DE3889927D1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
Akaji et al. Convergent synthesis of dolastatin 15 by solid phase coupling of an N-methylamino acid
ATE380867T1 (de) Lactoferrinrezeptorgen von moraxella
Ghelis et al. The folding of pancreatic elastase: independent domain refolding and inter-domain interaction
Sefler et al. Design, synthesis, and evaluation of a depsipeptide mimic of tendamistat
CA2217522A1 (en) Isolated frpb nucleic acid molecule and vaccine
Čeřovský et al. Protease‐catalyzed fragment condensation via substrate mimetic strategy: a useful combination of solid‐phase peptide synthesis with enzymatic methods
WO1996010579A1 (en) Blocking expression of virulence factors in s. aureus
KR910006483A (ko) 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
Konecsni et al. Twelve receptor molecules attach per viral particle of human rhinovirus serotype 2 via multiple modules
Burkhardt et al. Identification of a major antigenic epitope on CNBr‐fragment 11 of type II collagen recognized by murine autoreactive B cells

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900423

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid